Praxis Precision Medicines' stock has surged over 1,000% since April 2025, driven by positive clinical results for its CNS drug candidates ulixacaltamide and relutrigine, both expected to reach FDA review in 2026–2027. These drugs target large, underserved central nervous system markets with a combined peak sales potential exceeding $15 billion. The company holds $1.4 billion in cash, supporting its commercial expansion and reducing near-term financial risks. Despite the rapid share price increase, analysts see further upside potential, recommending cautious investment strategies such as covered calls.
Synopsys shares have fallen 15.45% this year despite strong fundamentals, including a 42.4% revenue increase and raised 2026 guidance. The company benefits from AI demand in silicon design and engineering simulation, with a price target of $496.97 im...
McDonald's has been upgraded to a Buy rating due to its attractive valuation that provides a margin of safety despite challenging consumer conditions. The company showed modest sales growth in Q2, strong customer loyalty, and a solid capital return y...
Medicus Pharma has confirmed the 200-microgram dose of its SkinJect patch for further studies targeting Gorlin syndrome, with FDA approval for a pivotal trial underway. The company is also exploring an out-licence for nodular basal cell carcinoma and...
Jim Cramer highlighted large flex-call option purchases in tech and energy stocks like Bloom Energy and Intel, raising questions about the buyer's identity. Weeks earlier, a House disclosure showed Pelosi's spouse had bought shares and call options i...
Five Dividend Kings—Procter & Gamble, Johnson & Johnson, Lowe’s, Emerson Electric, and Genuine Parts Company—are highlighted as top income stocks for retirees due to their decades-long records of annual dividend increases. These companies have mainta...
